Andre F et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 2022;40(16):1816-37. Abstract
Bardia A et al. Datopotamab deruxtecan (dato-DXd) in advanced triple-negative breast cancer (TNBC): Updated results from the phase 1 TROPION-PanTumor01 study. SABCS 2022;Abstract P6-10-03.
Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022;Abstract GS3-01.
Cani AK et al. Serial monitoring of genomic alterations in circulating tumor cells of ER-postitive/HER2-negative advanced breast cancer: Feasibility of precision oncology biomarker detection. Mol Oncol 2022;16(10):1969-85. Abstract
Ferraro E et al. Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer Treat Rev 2022;109:120432. Abstract
Jhaveri K et al. ER word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC. SABCS 2021;Abstract TF-1.
Jhaveri K et al. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Exp Rev Anticancer Ther 2021;21(10):1105-24. Abstract
Lambertini M et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation for ovarian function and fertility in premenopausal patients with early breast cancer: A systemic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-90. Abstract
Liu D et al. Characterization, management, and risk factors of hyperglycemia during PI3K and AKT inhibitor treatment. Cancer Med 2022;11(8):1796-804. Abstract
Meric-Berstam F et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer. SABCS 2022;Abstract PD13-08.
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer: Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Moore HCF et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372(10):923-32. Abstract
Oktay K et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;19(36):1994-2001. Abstract
Oliveira M et al. Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose phase 2 SERENA-2 trial. SABCS 2022;Abstract GS302.
Rugo HS et al. Sacituzumab govitecan vs treatment of physician’s choice: Efficacy by trop-2 expression in the TROPiCS-02 study of patients with HR+/HER2- metastatic breast cancer. SABCS 2022;Abstract GS1-11.
Shen S et al. Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic PIK3CA-mutant hormone receptor-positive breast cancer. ASCO 2022;Abstract TPS1113.
Smyth LM et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer 2021;7(1):44. Abstract
Sparano JA et al. Trial assigning individualized options for treatment (TAILORx): An update including 12-year event rates. SABCS 2022;Abstract GS1-05.
Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III CAPItello-291 trial. SABCS 2022;Abstract GS3-04.